预约演示
更新于：2026-08-16
Semaglutide (Novo Nordisk)
司美格鲁肽 (诺和诺德)
更新于：2026-08-16
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2017-12-05), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、突破性疗法 (中国)、优先审评 (美国)、局长国家优先审评券 (美国)、附条件批准 (加拿大)、优先审评 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 50953
来源: *****
关联
650
项与 司美格鲁肽 (诺和诺德) 相关的临床试验NCT07586150
Personalised Pharmaco-Lifestyle Interventions for Severe Mental Illnesses Enhanced by Digital Health and Immersive Technologies
NCT07430332
Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function
NCT07754045
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Oral LUM-201 as an Adjunct to Oral Semaglutide for Improving Physical Function in Older Adults With Obesity
100 项与 司美格鲁肽 (诺和诺德) 相关的临床结果
登录后查看更多信息
100 项与 司美格鲁肽 (诺和诺德) 相关的转化医学
登录后查看更多信息
100 项与 司美格鲁肽 (诺和诺德) 相关的专利（医药）
登录后查看更多信息
389
项与 司美格鲁肽 (诺和诺德) 相关的文献（医药）2026-10-01JOINT BONE SPINE
Role of the GAPDH-mediated glycolysis-senescence axis in osteoarthritis chondrocytes and its modulation by semaglutide
Article
作者: Zhu, Lin ; Wang, Leilei ; Liu, Dameng ; Wang, Yuanhang ; Pei, Lijia
OBJECTIVES:
This study aimed to identify key regulatory genes involved in chondrocyte senescence in osteoarthritis (OA) and to evaluate the therapeutic potential of the GLP-1 receptor agonist semaglutide.
METHODS:
Transcriptomic data of chondrocytes from OA and control groups were collected. Batch effects were corrected using Harmony, and differential expression analysis was performed with DESeq2 to identify significantly altered genes. Functional enrichment and pathway involvement were assessed using KEGG and Gene Set Enrichment Analysis (GSEA). Weighted gene co-expression network analysis (WGCNA) was applied to identify OA-related modules, and protein-protein interaction (PPI) networks were constructed to screen for hub genes. In vitro experiments included ROS detection, RT-PCR, and ELISA to evaluate oxidative stress, inflammatory mediators, and senescence-associated gene expression. Cell proliferation was assessed using CCK-8, and semaglutide treatment at different concentrations was applied to verify its regulatory effects.
RESULTS:
Transcriptomic analysis revealed significant upregulation of inflammatory and oxidative stress pathways in OA chondrocytes, accompanied by downregulation of cell cycle and DNA repair pathways, suggesting the accumulation of senescent cells. WGCNA and PPI network analyses identified GAPDH as a key hub gene, whose expression was markedly reduced in OA. In vitro validation confirmed decreased proliferative capacity, elevated ROS levels, and increased expression of p53, IL-6, and TGF-β in OA cells. Semaglutide treatment reversed GAPDH downregulation, improved proliferation, and reduced p53 and inflammatory cytokine levels, suggesting that it exerts protective effects through modulation of the glycolysis-senescence-inflammation axis.
CONCLUSION:
This study systematically elucidates the senescence-centered pathological characteristics of OA chondrocytes and identifies GAPDH as a pivotal regulator of glycolysis and senescence. Semaglutide alleviates OA progression by restoring GAPDH expression and modulating metabolic-senescence signaling. These findings provide a theoretical basis for metabolism- and senescence-targeted interventions in OA and offer new insights into potential molecular therapeutic targets.
2026-09-01RESPIRATORY MEDICINE
GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis
Article
作者: Altschul, David J ; Sharma, Sunil ; Praveen, Niharika ; Essibayi, Muhammed Amir ; Latifi, Shahrzad ; Lakhani, Dhairya A ; Colasurdo, Marco ; Dmytriw, Adam A ; Azzam, Ahmed Y ; Bathla, Girish ; Chen, Huanwen Alvin ; Rai, Pranjal ; Malhotra, Ajay ; Yedavalli, Vivek S ; Salim, Hamza A ; Gandhi, Dheeraj
BACKGROUND:
Glucagon-like peptide-1 receptor agonists (GLP-1As) confer cerebrovascular benefits in diabetes and obesity, but their long-term effects in obstructive sleep apnea (OSA), which is frequently associated with obesity and linked to poor cerebrovascular outcomes, remain unclear.
METHODS:
We conducted a retrospective cohort study using the TriNetX US Collaborative Network between January 1st 2016 to December 31st 2025. Adults with OSA were identified; exposure was initiation of a GLP-1A within 6 months before up to 1 month after OSA diagnosis. Propensity score matching was performed 1:1. Outcomes were assessed at 1, 3, and 5 years and included ischemic stroke, intracranial hemorrhage, emergency department visits, inpatient hospitalizations, and all-cause mortality. Kaplan-Meier analyses and Cox proportional hazards models were used. CPAP-restricted and tirzepatide-specific subgroup analyses were also performed.
RESULTS:
After matching, 438,844 patients were included in each cohort. Across 1-, 3-, and 5-year follow-up, GLP-1A exposure was associated with lower hazards of ischemic stroke (HRs, 0.75, 0.83, and 0.87), intracranial hemorrhage (HRs, 0.44, 0.56, and 0.61), emergency department visits (HRs, 0.77, 0.86, and 0.87), inpatient hospitalizations (HRs, 0.59, 0.67, and 0.69), and all-cause mortality (HRs, 0.38, 0.49, and 0.54; all p < 0.001). Associations were directionally consistent in CPAP-restricted and tirzepatide-specific subgroup analyses.
CONCLUSIONS:
In this large real-world cohort of patients with OSA, GLP-1A exposure was associated with lower hazards of cerebrovascular events, healthcare utilization, and all-cause mortality across 1-, 3-, and 5-year follow-up. These findings are hypothesis-generating and require validation in prospective studies evaluating incretin-based therapies as potential adjuncts to standard OSA management.
2026-09-01JOURNAL OF CLINICAL NEUROSCIENCE
GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis
Article
作者: Lakhani, Dhairya A ; Salim, Hamza A ; Praveen, Niharika ; Latifi, Shahrzad ; Aggarwal, Eishvauk ; Essibayi, Muhammed Amir ; Altschul, David J ; Kakadiya, Jay ; Dmytriw, Adam A ; Colasurdo, Marco ; Gandhi, Dheeraj ; Dhaduk, Vidhi ; Azzam, Ahmed Y ; Bathla, Girish ; Rai, Pranjal ; Chen, Huanwen Alvin ; Yedavalli, Vivek S ; Malhotra, Ajay
BACKGROUND:
Glucagon-like peptide-1 receptor agonists (GLP-1As) have demonstrated cardiovascular and cerebrovascular benefits in high-risk populations, but their impact in patients with acute ischemic stroke (AIS) requiring endovascular thrombectomy (EVT) remains uncertain.
METHODS:
We performed a retrospective cohort analysis using the TriNetX Network, identifying adults (≥18 years) with AIS treated with EVT from January 1, 2016 through December 31, 2025. Patients with GLP-1A exposure within three months prior to EVT constituted the exposure cohort; those without served as comparators. This pre-index window was specified to eliminate immortal time bias, with follow-up beginning on the EVT date for both cohorts. Three-year outcomes included all-cause mortality and inpatient hospitalizations. One-to-one propensity score matching was applied using demographic, comorbidity, medication, and metabolic variables including individual National Institute of Health Stroke Scale scores, Hemoglobin A1c, and body mass index.
RESULTS:
Among 286 GLP-1A-exposed and 19,263 unexposed EVT-treated patients, 261 matched pairs were analyzed. GLP-1A use was associated with lower all-cause mortality (11.5% vs 29.9%; HR 0.334, 95% CI 0.219-0.508) and fewer inpatient hospitalizations (39.8% vs 54.8%; HR 0.514, 95% CI 0.398-0.663), both p < 0.001.
CONCLUSIONS:
Among EVT-treated AIS patients, GLP-1A exposure within three months prior to EVT was associated with improved survival and reduced inpatient hospitalizations.
100 项与 司美格鲁肽 (诺和诺德) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10025 | 司美格鲁肽 (诺和诺德) |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏病 | 英国 | 2026-04-01 | |
| 肝纤维化 | 美国 | 2025-12-22 | |
| 肺纤维化 | 加拿大 | 2025-12-21 | |
| 代谢功能障碍相关脂肪性肝炎 | 美国 | 2025-08-15 | |
| 代谢功能障碍相关脂肪性肝炎 | 美国 | 2025-08-15 | |
| 慢性肾病 | 美国 | 2025-01-28 | |
| 慢性肾病 | 美国 | 2025-01-28 | |
| 脑卒中 | 澳大利亚 | 2024-12-16 | |
| 心肌梗塞 | 加拿大 | 2024-11-27 | |
| 心血管疾病 | 美国 | 2024-03-08 | |
| 肥胖 | 美国 | 2021-06-04 | |
| 超重 | 美国 | 2021-06-04 | |
| 2型糖尿病 | 美国 | 2017-12-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白蛋白尿 | 临床3期 | 加拿大 | 2022-03-14 | |
| 白蛋白尿 | 临床3期 | 德国 | 2022-03-14 | |
| 白蛋白尿 | 临床3期 | 荷兰 | 2022-03-14 | |
| 白蛋白尿 | 临床3期 | 西班牙 | 2022-03-14 | |
| 膝关节炎 | 临床3期 | 美国 | 2021-10-01 | |
| 膝关节炎 | 临床3期 | 加拿大 | 2021-10-01 | |
| 膝关节炎 | 临床3期 | 哥伦比亚 | 2021-10-01 | |
| 膝关节炎 | 临床3期 | 丹麦 | 2021-10-01 | |
| 膝关节炎 | 临床3期 | 法国 | 2021-10-01 | |
| 膝关节炎 | 临床3期 | 挪威 | 2021-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 201 | (Oral Semaglutide 50 mg) | 鬱遞築築夢窪糧襯壓築(積構夢鹽鏇顧憲網積蓋) = 願齋衊齋簾願顧餘齋鹹 糧鹹蓋繭憲選艱齋遞蓋 (餘糧範顧願鹽繭窪觸餘, 9.5) 更多 | - | 2026-08-14 | ||
(Oral Semaglutide Placebo) | 鬱遞築築夢窪糧襯壓築(積構夢鹽鏇顧憲網積蓋) = 餘壓窪壓製鑰憲願觸夢 糧鹹蓋繭憲選艱齋遞蓋 (餘糧範顧願鹽繭窪觸餘, 5.0) 更多 | ||||||
临床4期 | 1,018 | 鹹獵願鹽簾廠繭選範窪(膚艱餘廠憲築夢襯範選) = 壓醖鑰製獵觸網簾壓壓 壓選選憲遞衊衊壓繭繭 (鹽膚憲築齋繭積製醖糧, 1.463) 更多 | - | 2026-08-10 | |||
临床4期 | 120 | Placebo (Behavioral Treatment + Placebo (Weeks 0-60)) | 鹽夢憲廠鏇壓顧醖鏇鏇(範膚襯構壓積糧鏇廠襯) = 壓窪壓積壓淵網襯遞餘 鏇餘構憲鬱獵餘鹹憲鹹 (糧網簾鹽壓壓簾選構壓, 52.6) 更多 | - | 2026-08-03 | ||
(Behavioral Treatment + Medication (Weeks 0-60)) | 鹽夢憲廠鏇壓顧醖鏇鏇(範膚襯構壓積糧鏇廠襯) = 鬱獵憲鏇顧顧襯壓憲築 鏇餘構憲鬱獵餘鹹憲鹹 (糧網簾鹽壓壓簾選構壓, 37.2) 更多 | ||||||
临床3期 | 148 | 廠膚醖鬱繭膚獵糧餘鏇(遞窪憲窪齋壓顧糧夢遞) = 範選製鏇願觸廠積觸鏇 鑰淵艱網鹽艱襯蓋觸築 (鏇鹽壓醖餘糧襯願鏇憲 ) | 积极 | 2026-07-01 | |||
N/A | 12,500 | 夢廠築襯獵衊壓襯選築(願鑰簾糧憲齋壓獵獵構): RR = 1.08 (95.0% CI, 0.97 ~ 1.2) | 积极 | 2026-06-20 | |||
临床3期 | 262 | 網憲壓遞鏇網鹽淵構製(簾壓襯鹹遞窪憲襯網艱) = 艱顧壓鏇鬱鹹齋窪憲鏇 鹽鬱壓壓廠膚獵積鏇廠 (壓願鏇選膚餘鹹願鑰餘 ) 更多 | 积极 | 2026-06-20 | |||
網憲壓遞鏇網鹽淵構製(簾壓襯鹹遞窪憲襯網艱) = 鹽糧壓窪餘鹽壓願鬱鏇 鹽鬱壓壓廠膚獵積鏇廠 (壓願鏇選膚餘鹹願鑰餘 ) | |||||||
N/A | 45 | (Kidney Transplant Recipients + Type 2 Diabetes) | 壓齋鹹遞簾鹽餘構獵壓(齋衊構範衊膚餘醖廠簾) = 衊積蓋鏇構顧遞鏇衊襯 糧醖網繭範鹹網鏇壓憲 (鏇觸鹽觸淵廠夢蓋觸繭 ) | 积极 | 2026-06-20 | ||
临床3期 | 72 | 鹽淵壓網窪築餘齋選遞(憲顧糧廠襯淵繭遞範蓋) = 襯鹽網獵糧鹹襯遞簾繭 選築鏇夢網築淵鏇積襯 (窪製觸積製遞齋艱獵餘 ) | 积极 | 2026-06-20 | |||
Placebo | 鹽淵壓網窪築餘齋選遞(憲顧糧廠襯淵繭遞範蓋) = 鹹鏇選齋艱製衊淵艱願 選築鏇夢網築淵鏇積襯 (窪製觸積製遞齋艱獵餘 ) | ||||||
N/A | 177 | (Diabetes) | 願餘夢築齋簾遞鬱夢鹹(廠獵齋鹽觸積鏇襯簾襯) = 簾築顧構選選構艱製膚 鹽構壓窪艱窪積鏇構齋 (繭築窪襯鏇顧範鬱獵遞 ) 更多 | 积极 | 2026-06-20 | ||
N/A | 66 | (Uncontrolled Type 2 Diabetes) | 壓積艱醖積糧窪築範顧(鑰壓簾鹽艱製餘鹹襯淵) = improved significantly from 54.8±23.3% at baseline to 78.1±18.9% (95% CI 9.5-25.5, P<0.001) 獵遞衊積鹽餘鏇糧醖夢 (觸網蓋膚鏇廠鹽鹹窪艱 ) 更多 | 积极 | 2026-06-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用